Business
Last patient visit completed on schedule in Phase 1b clinical trial of HER-096 for Parkinson’s disease
Patient visits are now complete in the final cohort of Phase 1b trial, consisting of Parkinson’s disease patients receiving 300 mg doses of HER-096 or placebo twice weekly over a four-week periodPrimary objective is to assess the safety, tolerability and pharmacokinetics of repeated subcutaneous doses of HER-096; the trial will also evaluate selected biomarkers, and aims to identify novel treatment response biomarkers and monitor symptoms associated with Parkinson’s diseaseTopline Phase 1b resul
About this update from Herantis Pharma Plc
[{"type":"image","alt":"Herantis Pharma plc","displaySize":"","headline":null,"caption":"Herantis Pharma plc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":51,"url":"https://media.zenfs.com/en/globenewswire.com/6e517fc0c42b7af0b4fe04e9fd7ab646"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TztkX3djp9fmQ02UkZu7vQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTcxO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/6e517fc0c42b7af0b4fe04e9fd7ab646","width":300,"height":51}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Patient visits are now complete in the final cohort of Phase 1b trial, consisting of Parkinson’s disease patients receiving 300 mg doses of HER-096 or placebo twice weekly over a four-week period","length":195,"tagName":"p"}]},{"val":[{"type":"text","content":"Primary objective is to assess the safety, tolerability and pharmacokinetics of repeated subcutaneous doses of HER-096; the trial will also evaluate selected biomarkers, and aims to identify novel treatment response biomarkers and monitor symptoms associated with Parkinson’s disease","length":283,"tagName":"p"}]},{"val":[{"type":"text","content":"Topline Phase 1b results are expected within six-to-nine weeks, following data unblinding, analysis and interpretation","length":118,"tagName":"p"}]},{"val":[{"type":"text","content":"The full dataset, including biomarker data, is expected before the end of the year","length":82,"tagName":"p"}]},{"val":[{"type":"text","content":"Trial is funded by the Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Parkinson’s UK","length":99,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":777,"olType":false},{"type":"text","content":"Espoo, Finland, 14 August 2025: Herantis Pharma Plc ("Herantis"), a clinical-stage company developing disease-modifying therapies to stop Parkinson’s disease, announces that the last patient visit has now been completed on schedule in the Phase 1b clinical trial evaluating the safety and tolerability of HER-096 in patients with Parkinson’s disease.","length":360,"tagName":"p"},{"type":"text","content":"Antti Vuolanto, CEO of Herantis Pharma, said: “We are pleased to have completed all patient dosing and follow-up visits in our Phase 1b study of HER-096. With this milestone reached, we will now concentrate on completing the data an...